<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33074">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676089</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AB2-02</org_study_id>
    <secondary_id>2015-000717-40</secondary_id>
    <nct_id>NCT02676089</nct_id>
  </id_info>
  <brief_title>TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)</brief_title>
  <acronym>TRIGGER</acronym>
  <official_title>A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT® IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority of CHF 5993 200/6/12.5 µg pMDI
      (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus
      glycopyrronum bromide) versus CHF 1535 200/6 µg pMDI (fixed combination of extrafine
      beclometasone dipropionate plus formoterol fumarate) and to compare the effect of CHF 5993
      200/6/12.5 µg pMDI vs CHF 5993 200/6/12.5 µg plus open-label Tiotropium 2.5µg, in terms of
      lung functions parameters and rate of exacerbations, as well as to assess its safety and
      some health economics outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose FEV1 (Forced Expiratory Volume in the first second)</measure>
    <time_frame>Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of moderate and severe asthma exacerbations rate</measure>
    <time_frame>Week 0 to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (Peak of Forced Expiratory Volume in the first second) within 3 hours post-dose</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in morning PEF (Peak Expiratory Flow)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of severe asthma exacerbations rate</measure>
    <time_frame>Week 0 to week 52</time_frame>
    <description>Pooled analysis of CCD-05993AB1-03 and CCD-05993AB2-02 trials</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events and Adverse Drug reactions</measure>
    <time_frame>Up to Week 52</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Collection of Health Economics outcomes</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Total use of healthcare resources and absence from work</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1435</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 5993 200/6/12.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A:
CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 200/6 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B:
CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment C (open-label arm):
CHF 1535 200/6 µg: 2 inhalations bid
+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 200/6/12.5 µg</intervention_name>
    <arm_group_label>CHF 5993 200/6/12.5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 200/6 µg</intervention_name>
    <arm_group_label>CHF 1535 200/6 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg</intervention_name>
    <arm_group_label>CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of asthma ≥ 1 year and diagnosed before 40 years old

          -  Uncontrolled asthma with double therapy only on high doses of Inhaled CorticoSteroid
             (ICS) in combination with Long-Acting Beta2 Agonist (LABA) with ACQ-7 (Asthma Control
             Questionnaire) ≥1.5

          -  Pre-bronchodilator FEV1 &lt;80% of the predicted normal value

          -  Positive reversibility test

          -  At least 1 documented asthma exacerbation in the previous year

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

          -  Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks
             prior screening

          -  Current smoker or ex-smoker (&gt;= 10 packs year)

          -  Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks
             prior screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgio Walter Canonica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine, Genoa, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiesi Clinical Trial Info</last_name>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 380701</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 13, 2016</lastchanged_date>
  <firstreceived_date>February 3, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma, Anticholinergics, Triple combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
